QIBA FDG-PET Biomarker Committee (BC) Call
01 September 2017 at 9 AM CT
Call Summary

In attendance:

Rathan Subramaniam, MD, PhD, MPH (Co-Chair)
John Sunderland, PhD (Co-Chair)
Scott Wollenweber, PhD (Co-Chair)
Ronald Boellaard, PhD
Howard Higley, PhD
Paul Kinahan, PhD
Michael Knopp, MD, PhD
Martin Lodge, PhD
Nancy Obuchowski, PhD
Amy Perkins, PhD
Eric Perlman, MD
Anne Smith, PhD
Mitsuaki Tatsumi, MD
Richard Wahl, MD, FACR
Jeffrey Yap, PhD

RSNA
Joe Koudelik
Julie Lisiecki

Moderator: Dr. Wollenweber

FDG-PET Poster for RSNA 2017

- Dr. Perlman reviewed an Excel spreadsheet assembled by the Nuclear Medicine Leadership Team to aid with organizing content for the posters
- The 2016 poster was reviewed to determine what updates were needed
- All were reminded of the guidelines from Drs. Jackson and Guimaraes:
  - Organizational Structure Updates
  - Profile Development Status
  - Profile Impact/Implications for Clinical Trials and Patient Care (new focus for 2017)
  - Conformance Procedure Update
  - Groundwork Project Status/Results (optional)

- Other updates include:
  - Groundwork projects
    - Drs. Lodge and Turkington to work on these 2 panel sections
  - Profile stages
  - Details regarding clinical trials
    - Drs. Sunderland and Subramaniam to work on this panel section
  - The QIBA/fNIH FDG-PET biomarker qualification efforts (Dr. Higley)
- Other topics to consider:
  - Prognostic claim vs. predictive claim
  - How FDG-PET is making a difference
  - Gap analysis between QIBA FDG-PET checklist and others
- Goal is to have all of the individual panels completed by the end of September so that a complete poster draft can be discussed on the October 6th call
- Panel sections to be edited are numbered/positioned as follows:
  - 1 3 5 7
  - 2 4 6 8

ECOG-ACRIN collaboration

- The BC is asking for the following from ECOG-ACRIN in support of the FDG-PET Profile:
  - Funding for test-re-test studies
  - Dedicated time for core lab staff to manage these studies
- Drs. Subramaniam and Sunderland plan to begin work on a protocol template using the ECOG-ACRIN imaging manual to be ready for implementation once updates are received

ClinicalTrials.Gov

- Related to the ECOG-ACRIN effort, the group would like to inventory quantitative FDG studies to determine impact on clinical trials
- A metric is to be identified to demonstrate this impact
- It was suggested that one of Dr. Wahl's fellows might be able to decipher some information from the www.clinicaltrials.gov site

- A survey of the NM community may be needed if PI follow-up is warranted
- Dr. Sunderland pointed out that it may be difficult to determine accurate details from the clinicaltrials.gov site, as there is a lack of detail regarding whether quantitation is being used
- Other suggestions involved surveying pharma and/or conducting a PubMed search
    - Pharma sometimes conducts smaller studies which remain unpublished; some details regarding quantitation may be included in these studies
    - It was also suggested that PIs identified through www.clinicaltrials.gov could be contacted and asked if quantitation was used in their trials

***Radiology* article update**

- A special report article has been submitted to *Radiology* with the FDG-PET checklist
- If accepted, supplementary materials related to the Profile may be added

Nuclear Medicine WebEx Schedule:

9/8	PET Amyloid BC
9/15	SPECT BC
9/29	NM Coordinating Ctte
10/6	FDG-PET BC
10/13	PET Amyloid BC
10/20	SPECT BC
10/27	NM Leadership (TBD)

SAVE-THE-DATE: **QIBA Working Meeting at RSNA 2017** | Wednesday, November 29, 2:30-6 pm – Lakeside Center